These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 7531616

  • 1. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

  • 2. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.
    Cancer Res; 1995 Jun 15; 55(12):2627-34. PubMed ID: 7540106
    [Abstract] [Full Text] [Related]

  • 3. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ.
    Cancer Res; 1989 Jul 15; 49(14):3783-8. PubMed ID: 2472198
    [Abstract] [Full Text] [Related]

  • 4. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM, van Buitenen F, Hekman A, Melief CJ.
    Cancer Res; 1990 Sep 15; 50(18):5767-72. PubMed ID: 1697500
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H, Moroyama T, Mendelsohn J.
    Cancer Res; 1986 Nov 15; 46(11):5592-8. PubMed ID: 3756906
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody.
    Hooijberg E, Sein JJ, van den Berk PC, Hekman A.
    Hybridoma; 1996 Feb 15; 15(1):23-31. PubMed ID: 9064283
    [Abstract] [Full Text] [Related]

  • 7. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
    van Oosterhout YV, van den Herik-Oudijk IE, Wessels HM, de Witte T, van de Winkel JG, Preijers FW.
    Cancer Res; 1994 Jul 01; 54(13):3527-32. PubMed ID: 7516821
    [Abstract] [Full Text] [Related]

  • 8. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS.
    Cancer Res; 1992 Dec 01; 52(23):6476-81. PubMed ID: 1423295
    [Abstract] [Full Text] [Related]

  • 9. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA.
    Leukemia; 2002 Jan 01; 16(1):60-6. PubMed ID: 11840264
    [Abstract] [Full Text] [Related]

  • 10. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y.
    Cancer Res; 2008 Apr 01; 68(7):2400-8. PubMed ID: 18381448
    [Abstract] [Full Text] [Related]

  • 11. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 01; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 12. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

  • 13. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 15; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 14. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W, Shau H, Hadley CG, Morgan AC, Reisfeld RA, Cheresh DA, Mitchell MS.
    Cancer Res; 1990 Oct 01; 50(19):6311-5. PubMed ID: 2400994
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.
    Cancer Res; 1992 Oct 15; 52(20):5713-9. PubMed ID: 1394194
    [Abstract] [Full Text] [Related]

  • 16. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA.
    Cancer Res; 1989 Jun 01; 49(11):2857-61. PubMed ID: 2720646
    [Abstract] [Full Text] [Related]

  • 17. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.
    Cancer Res; 2003 Sep 01; 63(17):5595-600. PubMed ID: 14500400
    [Abstract] [Full Text] [Related]

  • 18. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, Jallal B, Herbst R.
    Br J Haematol; 2011 Nov 01; 155(4):426-37. PubMed ID: 21902688
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 20. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.